Health Care [ 12/12 ] | Biotechnology [ 62/74 ]
NASDAQ | Common Stock
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases.
The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.
It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders.
The company has licensing agreements with LG Chem, Ltd; Ipsen PharmaS. A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015.
Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 6, 24 | -0.69 Increased by +15.85% | -0.71 Increased by +2.82% |
| May 7, 24 | -2.35 Decreased by -155.43% | -2.16 Decreased by -8.80% |
| Feb 22, 24 | -0.70 Increased by +6.67% | -0.70 |
| Nov 7, 23 | -0.76 Increased by +3.80% | -0.74 Decreased by -2.70% |
| Aug 1, 23 | -0.82 Increased by +7.87% | -0.79 Decreased by -3.80% |
| May 2, 23 | -0.92 Increased by +12.38% | -0.73 Decreased by -26.03% |
| Mar 1, 23 | -0.75 Increased by +11.76% | -0.81 Increased by +7.41% |
| Nov 8, 22 | -0.79 Decreased by -12.86% | -1.00 Increased by +21.00% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 33.25 M Increased by +47.76% | -44.97 M Decreased by -1.83% | Decreased by -135.24% Increased by +31.08% |
| Jun 30, 24 | 29.08 M Increased by +51.28% | -32.26 M Increased by +30.92% | Decreased by -110.95% Increased by +54.34% |
| Mar 31, 24 | 25.97 M Increased by +126.41% | -141.37 M Decreased by -172.78% | Decreased by -544.43% Decreased by -20.48% |
| Dec 31, 23 | 24.23 M Increased by +175.70% | -41.63 M Increased by +2.91% | Decreased by -171.80% Increased by +64.79% |
| Sep 30, 23 | 22.50 M Increased by +425.30% | -44.16 M Decreased by -4.02% | Decreased by -196.25% Increased by +80.20% |
| Jun 30, 23 | 19.22 M Increased by +112.01% | -46.70 M Decreased by -4.00% | Decreased by -242.98% Increased by +50.95% |
| Mar 31, 23 | 11.47 M Increased by +665.62% | -51.83 M Increased by +1.91% | Decreased by -451.89% Increased by +87.19% |
| Dec 31, 22 | 8.79 M Increased by +383.76% | -42.88 M Decreased by -0.04% | Decreased by -487.86% Increased by +79.32% |